Dashboard
Manage Tickers

ORGOOrganogenesis Holdings Inc.

Nasdaq organogenesis.com


$ 2.50 $ 0.00 (0 %)    

Friday, 03-May-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 2.49
$ 2.62
$ 0.00 x 0
$ 0.00 x 0
$ 2.46 - $ 2.64
$ 1.93 - $ 4.71
895,051
na
330.54M
$ 1.17
$ 66.84
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-29-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-01-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-16-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-09-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-09-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 03-18-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-14-2018 12-31-2017 10-K
26 11-14-2017 09-30-2017 10-Q
27 08-11-2017 06-30-2017 10-Q
28 05-12-2017 03-31-2017 10-Q
29 03-28-2017 12-31-2016 10-K
30 11-18-2016 09-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

organogenesis-shares-are-trading-higher-after-the-company-announced-that-its-phase-3-randomized-control-trial-evaluating-the-safety-and-efficacy-of-renu-achieved-its-primary-endpoint
Organogenesis shares are trading higher af...
05/02/2024 11:45:34

organogenesis-achieves-primary-endpoint-in-phase-3-clinical-trial-of-renu-for-knee-osteoarthritis
Organogenesis Achieves Primary Endpoint In...
05/02/2024 11:44:04

 Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p<0.0001) maintenance o...

why-caterpillar-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Caterpillar Shares Are Trading Lower B...
04/25/2024 17:57:17

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
04/25/2024 16:31:09

organogenesis-announced-favorable-ruling-from-united-states-district-court-dismissing-securities-fraud-case
Organogenesis Announced Favorable Ruling F...
04/03/2024 11:33:30

cantor-fitzgerald-reiterates-overweight-on-organogenesis-hldgs-maintains-5-price-target
Cantor Fitzgerald Reiterates Overweight on...
03/01/2024 14:35:05

Cantor Fitzgerald analyst Ross Osborn reiterates Organogenesis Hldgs (NASDAQ:ORGO) with a Overweight and maintains $5 price ...

organogenesis-holdings-sees-fy24-revenue-445m-470m-vs-455949m-est
Organogenesis Holdings Sees FY24 Revenue $...
02/29/2024 21:38:37

recap-organogenesis-hldgs-q4-earnings
Recap: Organogenesis Hldgs Q4 Earnings
02/29/2024 21:15:13

organogenesis-hldgs-q4-2023-gaap-eps-0010-inline-sales-99651m-miss-109050m-estimate
Organogenesis Hldgs Q4 2023 GAAP EPS $0.01...
02/29/2024 21:13:59

Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.010 per share which met the analyst consensus estimate. Th...

earnings-scheduled-for-february-29-2024
Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

a-preview-of-organogenesis-hldgss-earnings
A Preview Of Organogenesis Hldgs's Earnings
02/28/2024 19:01:52

cantor-fitzgerald-initiates-coverage-on-organogenesis-hldgs-with-overweight-rating-announces-price-target-of-5
Cantor Fitzgerald Initiates Coverage On Or...
02/07/2024 12:29:23

Cantor Fitzgerald analyst Ross Osborn initiates coverage on Organogenesis Hldgs (NASDAQ:ORGO) with a Overweight rating and a...

why-reneo-pharmaceuticals-shares-are-trading-higher-by-around-14-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Reneo Pharmaceuticals Shares Are Tradi...
12/27/2023 19:11:57

Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an ac...

meta-to-rally-over-18-here-are-10-top-analyst-forecasts-for-wednesday
Meta To Rally Over 18%? Here Are 10 Top An...
12/27/2023 14:06:31

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

btig-maintains-buy-on-organogenesis-hldgs-raises-price-target-to-6
BTIG Maintains Buy on Organogenesis Hldgs,...
12/27/2023 12:27:57

BTIG analyst Ryan Zimmerman maintains Organogenesis Hldgs (NASDAQ:ORGO) with a Buy and raises the price target from $4 to $6.

morgan-stanley-maintains-equal-weight-on-organogenesis-hldgs-raises-price-target-to-35
Morgan Stanley Maintains Equal-Weight on O...
11/14/2023 14:31:27

Morgan Stanley analyst Drew Ranieri maintains Organogenesis Hldgs (NASDAQ:ORGO) with a Equal-Weight and raises the price tar...

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
11/10/2023 17:31:48

organogenesis-sees-fy23-net-revenue-433m-443m
Organogenesis Sees FY23 Net Revenue $433M-...
11/09/2023 21:48:55

organogenesis-q3-eps-002-net-revenue-1085m-vs-1114m-est
Organogenesis Q3 EPS $0.02, Net Revenue $1...
11/09/2023 21:48:13

earnings-scheduled-for-november-9-2023
Earnings Scheduled For November 9, 2023
11/09/2023 11:52:51

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on re...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION